Pembrolizumab 200 mg

BIOLOGICAL10 trials

Sponsors

Merck Sharp & Dohme LLC, Inhibrx Biosciences, Inc, Melanoma Institute Australia

Conditions

Carcinoma, Non-Small-Cell LungCutaneous MelanomaGastric CancerHead and Neck CancerHead and Neck NeoplasmsMelanomaMetastatic Castration-Resistant Prostate CancerMucosal Melanoma

Phase 1

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

CompletedNCT01840579

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumor

Start: 2013-04-26End: 2020-02-28Updated: 2021-06-22

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

RecruitingNCT02861573

Merck Sharp & Dohme LLCMetastatic Castration-Resistant Prostate Cancer

Start: 2016-11-17End: 2028-07-24Target: 1200Updated: 2026-02-17

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

CompletedNCT02862457

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung, Neoplasms

Start: 2016-08-23End: 2020-11-20Updated: 2022-08-19

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Active, not recruitingNCT04198766

Inhibrx Biosciences, IncGastric Cancer, Head and Neck Cancer, Melanoma +4

Start: 2019-12-10End: 2027-05-12Updated: 2025-12-18

Phase 2

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

CompletedNCT03631784

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer

Start: 2018-10-19End: 2024-03-19Updated: 2025-03-25

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

RecruitingNCT06999980

Melanoma Institute AustraliaCutaneous Melanoma, Mucosal Melanoma

Start: 2026-02-09End: 2038-01-01Target: 494Updated: 2026-02-19

Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

CompletedNCT02578680

Merck Sharp & Dohme LLCNon-Small-Cell Lung Carcinoma

Start: 2016-01-15End: 2023-06-22Updated: 2024-09-20

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Active, not recruitingNCT03765918

Merck Sharp & Dohme LLCHead and Neck Neoplasms

Start: 2018-12-17End: 2026-09-10Updated: 2025-08-20

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

CompletedNCT03950674

Merck Sharp & Dohme LLCNon-Small-Cell Lung Carcinoma

Start: 2016-02-22End: 2023-06-22Updated: 2024-06-10

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Active, not recruitingNCT04624204

Merck Sharp & Dohme LLCSmall Cell Lung Cancer

Start: 2020-12-08End: 2027-10-28Target: 672Updated: 2025-07-02

Related Papers

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.

2026-02-23

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058

The Journal of Immunology2025-11-01

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.

JCO Oncology Practice2025-10-01

Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.

2025-08-11

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

New England Journal of Medicine2025-06-18129 citations

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.

2025-06-11

Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study.

Journal of Clinical Oncology2025-05-286 citations

Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).

Journal of Clinical Oncology2025-05-281 citations

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Journal of Clinical Oncology2025-05-28

Abstract CT001: Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study

Cancer Research2025-05-227 citations

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

Nature Communications2025-05-178 citations

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Journal for ImmunoTherapy of Cancer2025-05-014 citations

A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.

2025-03-03

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Cell Reports Medicine2024-11-016 citations

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

2024-06-253 citations

Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.

Journal of Clinical Oncology2024-06-015 citations

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

Journal of Thoracic Oncology2024-04-1834 citations

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.

2024-03-264 citations

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

2024-03-029 citations

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.

2024-02-01

83 more papers not shown